Experimental Challenges to Targeting Poorly Characterized GPCRs. Uncovering the Therapeutic Potential for Free Fatty Acid Receptors

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 175-218

  Hudson, B D ^a   Smith, NicolaJ ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

FFA1; FFA2; FFA3; Free fatty acid; GPR120; GPR84

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40; G PROTEIN COUPLED RECEPTOR 41; G PROTEIN COUPLED RECEPTOR 42; G PROTEIN COUPLED RECEPTOR 43; G PROTEIN COUPLED RECEPTOR 84; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 4; LIGAND; LONG CHAIN FATTY ACID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

BOOK; CYTOKINE PRODUCTION; GENE INSERTION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 80052684905     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00006-3     Document Type: Chapter

References (187)

1. Ahren B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Current Diabetes Research 2007, 7:340-347.
2. Alquier T., Poitout V. GPR40: Good cop, bad cop?. Diabetes 2009, 58:1035-1036.
3. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods in Neuroscience 1995, 25:366-428.
4. Bartoschek S., Klabunde T., Defossa E., Dietrich V., Stengelin S., Griesinger C., et al. Drug design for G-protein-coupled receptors by a ligand-based NMR method. Angewandte Chemie 2010, 49:1426-1429.
5. Becker O.M., Marantz Y., Shacham S., Inbal B., Heifetz A., Kalid O., et al. G protein-coupled receptors: In silico drug discovery in 3D. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11304-11309.
6. Bharate S.B., Nemmani K.V., Vishwakarma R.A. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): An emerging target for type 2 diabetes. Expert Opinion on Therapeutic Patents 2009, 19:237-264.
7. Bharate S.B., Rodge A., Joshi R.K., Kaur J., Srinivasan S., Kumar S.S., et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorganic & Medicinal Chemistry Letters 2008, 18:6357-6361.
8. Bjursell M., Admyre T., Goransson M., Marley A.E., Smith D.M., Oscarsson J., et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. American Journal of Physiology. Endocrinology and Metabolism 2011, 300:E211-E220.
9. Bouchard C., Page J., Bedard A., Tremblay P., Vallieres L. G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia 2007, 55:790-800.
10. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules. British Journal of Pharmacology 2006, 148:619-628.
11. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. The Journal of Biological Chemistry 2003, 278:11303-11311.
12. Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. The Journal of Biological Chemistry 2003, 278:11312-11319.
13. Brownlie R., Mayers R.M., Pierce J.A., Marley A.E., Smith D.M. The Long-chain fatty acid receptor, GPR40, and glucolipotoxicity: Investigations using GPR40-knockout mice. Biochemical Society Transactions 2008, 36:950-954.
14. Bunzow J.R., Van Tol H.H., Grandy D.K., Albert P., Salon J., Christie M., et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988, 336:783-787.
15. Bylund D.B., Deupree J.D., Toews M.L. Radioligand-binding methods for membrane preparations and intact cells. Methods in Molecular Biology 2004, 259:1-28.
16. Bylund D.B., Toews M.L. Radioligand binding methods: Practical guide and tips. The American Journal of Physiology 1993, 265:L421-L429.
17. Calder P.C. Polyunsaturated fatty acids and inflammation. Biochemical Society Transactions 2005, 33:423-427.
18. Cherbut C., Ferrier L., Roze C., Anini Y., Blottiere H., Lecannu G., et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. The American Journal of Physiology 1998, 275:G1415-G1422.
19. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
20. Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330:1091-1095.
21. Christiansen E., Urban C., Merten N., Liebscher K., Karlsen K.K., Hamacher A., et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. Journal of Medicinal Chemistry 2008, 51:7061-7064.
22. Chung S., Funakoshi T., Civelli O. Orphan GPCR research. British Journal of Pharmacology 2008, 153:S339-S346.
23. Civelli O., Saito Y., Wang Z., Nothacker H.P., Reinscheid R.K. Orphan GPCRs and their ligands. Pharmacology & Therapeutics 2006, 110:525-532.
24. Congreve M., Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. British Journal of Pharmacology 2010, 159:986-996.
25. Congreve M., Murray C.W., Blundell T.L. Structural biology and drug discovery. Drug Discovery Today 2005, 10:895-907.
26. Dass N.B., John A.K., Bassil A.K., Crumbley C.W., Shehee W.R., Maurio F.P., et al. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Neurogastroenterology and Motility 2007, 19:66-74.
27. Del Guerra S., Bugliani M., D'Aleo V., Del Prato S., Boggi U., Mosca F., et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: The role of type 2 diabetes and fatty acids. Nutrition, Metabolism, and Cardiovascular Diseases 2010, 20:22-25.
28. Defossa E., Goerlitzer J., Klabunde T., Drosou V., Stengelin S., Haschke G., et al. 4,5-Diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use therof as medicaments 2007, Sanofi-aventis, WO2007131620.
29. Dixon R.A., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G., Frielle T., et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
30. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
31. Eglen R.M., Bosse R., Reisine T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay and Drug Development Technologies 2007, 5:425-451.
32. El-Assaad W., Buteau J., Peyot M.L., Nolan C., Roduit R., Hardy S., et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003, 144:4154-4163.
33. Engel S., Skoumbourdis A.P., Childress J., Neumann S., Deschamps J.R., Thomas C.J., et al. A virtual screen for diverse ligands: Discovery of selective G protein-coupled receptor antagonists. Journal of the American Chemical Society 2008, 130:5115-5123.
34. Evers A., Klabunde T. Structure-based drug discovery using GPCR homology modeling: Successful virtual screening for antagonists of the alpha1A adrenergic receptor. Journal of Medicinal Chemistry 2005, 48:1088-1097.
35. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13780-13785.
36. Fredriksson R., Hoglund P.J., Gloriam D.E., Lagerstrom M.C., Schioth H.B. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Letters 2003, 554:381-388.
37. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular Pharmacology 2003, 63:1256-1272.
38. Fredriksson R., Schioth H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Molecular Pharmacology 2005, 67:1414-1425.
39. Fujiwara K., Maekawa F., Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: Mediation by PLC and L-type Ca2+ channel and link to insulin release. American Journal of Physiology. Endocrinology and Metabolism 2005, 289:E670-E677.
40. Galvez J., Rodriguez-Cabezas M.E., Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Molecular Nutrition & Food Research 2005, 49:601-608.
41. Garrido D.M., Corbett D.F., Dwornik K.A., Goetz A.S., Littleton T.R., McKeown S.C., et al. Synthesis and activity of small molecule GPR40 agonists. Bioorganic & Medicinal Chemistry Letters 2006, 16:1840-1845.
42. Ge H., Li X., Weiszmann J., Wang P., Baribault H., Chen J.L., et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008, 149:4519-4526.
43. Gehrmann W., Elsner M., Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic beta-cells. Diabetes, Obesity & Metabolism 2010, 12:149-158.
44. Gotoh C., Hong Y.H., Iga T., Hishikawa D., Suzuki Y., Song S.H., et al. The regulation of adipogenesis through GPR120. Biochemical and Biophysical Research Communications 2007, 354:591-597.
45. Greenough W.B., Crespin S.R., Steinberg D. Hypoglycaemia and hyperinsulinaemia in response to raised free-fatty-acid levels. Lancet 1967, 23:1334-1336.
46. Guo Z.D., Suga H., Okamura M., Takeda S., Haga T. Receptor-Gα fusion proteins as a tool for ligand screening. Life Sciences 2001, 68:2319-2327.
47. Hamid Y.H., Vissing H., Urhammer S.A., Pyke C., Hansen S.K., Glumer C., et al. Studies of relationships between variation of the human G protein-coupled receptor 40 gene and type 2 diabetes and insulin release. Diabetes Metabolism 2005, 22:74-80.
48. Hara T., Hirasawa A., Sun Q., Koshimizu T.A., Itsubo C., Sadakane K., et al. Flow cytometry-based binding assay for GPR40 (FFAR1; free fatty acid receptor 1). Molecular Pharmacology 2009, 75:85-91.
49. Hara T., Hirasawa A., Sun Q., Sadakane K., Itsubo C., Iga T., et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn-Schmiedeberg's Archives of Pharmacology 2009, 380:247-255.
50. Hardy S., St-Onge G.G., Joly E., Langelier Y., Prentki M. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. The Journal of Biological Chemistry 2005, 280:13285-13291.
51. Harig J.M., Soergel K.H., Komorowski R.A., Wood C.M. Treatment of diversion colitis with short-chain-fatty acid irrigation. The New England Journal of Medicine 1989, 320:23-28.
52. Harrison C., Traynor J.R. The [35S]GTPgammaS binding assay: Approaches and applications in pharmacology. Life Sciences 2003, 74:489-508.
53. He W., Miao F.J., Lin D.C., Schwandner R.T., Wang Z., Gao J., et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004, 429:188-193.
54. Hetenyi C., Maran U., Garcia-Sosa A.T., Karelson M. Structure-based calculation of drug efficiency indices. Bioinformatics 2007, 23:2678-2685.
55. Higdon J.V., Delage B., Williams D.E., Dashwood R.H. Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharmacological Research 2007, 55:224-236.
56. Hirasawa A., Hara T., Katsuma S., Adachi T., Tsujimoto G. Free fatty acid receptors and drug discovery. Biological & Pharmaceutical Bulletin 2008, 31:1847-1851.
57. Hirasawa A., Itsubo C., Sadakane K., Hara T., Shinagawa S., Koga H., et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochemical and Biophysical Research Communications 2008, 365:22-28.
58. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 2005, 11:90-94.
59. Holst J.J., Deacon C., Toft-Nielsen M.B., Bjerre-Knudsen L. On the treatment of diabetes mellitus with glucagon-like peptide-1. Annals of the New York Academy of Sciences 1998, 865:336-343.
60. Hong Y.H., Nishimura Y., Hishikawa D., Tsuzuki H., Miyahara H., Gotoh C., et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005, 146:5092-5099.
61. Hopkins A.L., Groom C.R. The druggable genome. Nature Reviews. Drug Discovery 2002, 1:727-730.
62. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9:430-431.
63. Hu H., He L.Y., Gong Z., Li N., Lu Y.N., Zhai Q.W., et al. A novel class of antagonists for the FFAs receptor GPR40. Biochemical and Biophysical Research Communications 2009, 390:557-563.
64. Humphries P.S., Benbow J.W., Bonin P.D., Boyer D., Doran S.D., Frisbie R.K., et al. Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorganic & Medicinal Chemistry Letters 2009, 19:2400-2403.
65. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
66. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
67. Jacoby E., Bouhelal R., Gerspacher M., Seuwen K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006, 1:761-782.
68. Jenkins L., Alvarez-Curto E., Campbell K., de Munnik S., Canals M., Schlyer S., et al. Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα13 and β-arrestin-2. British Journal of Pharmacology 2011, 162:733-748.
69. Kaji I., Karaki S.I., Tanaka R., Kuwahara A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. Journal of Molecular Histology 2011, 42:27-38.
70. Karaki S., Mitsui R., Hayashi H., Kato I., Sugiya H., Iwanaga T., et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell and Tissue Research 2006, 324:353-360.
71. Karaki S., Tazoe H., Hayashi H., Kashiwabara H., Tooyama K., Suzuki Y., et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. Journal of Molecular Histology 2008, 39:135-142.
72. Katsuma S., Hatae N., Yano T., Ruike Y., Kimura M., Hirasawa A., et al. Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. The Journal of Biological Chemistry 2005, 280:19507-19515.
73. Kebede M., Alquier T., Latour M.G., Semache M., Tremblay C., Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008, 57:2432-2437.
74. Keen M. The problems and pitfalls of radioligand binding. Methods in Molecular Biology 1995, 41:1-16.
75. Klabunde T., Hessler G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3:928-944.
76. Kostenis E., Waelbroeck M., Milligan G. Techniques: Promiscuous Gα proteins in basic research and drug discovery. Trends in Pharmacological Sciences 2005, 26:595-602.
77. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochemical and Biophysical Research Communications 2003, 301:406-410.
78. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:9997-10002.
79. Lagerstrom M.C., Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews. Drug Discovery 2008, 7:339-357.
80. Lan H., Hoos L.M., Liu L., Tetzloff G., Hu W., Abbondanzo S.J., et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008, 57:2999-3006.
81. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
82. Lattin J.E., Schroder K., Su A.I., Walker J.R., Zhang J., Wiltshire T., et al. Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Research 2008, 4:5.
83. Le Poul E., Loison C., Struyf S., Springael J.Y., Lannoy V., Decobecq M.E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. The Journal of Biological Chemistry 2003, 278:25481-25489.
84. Lee T., Schwandner R., Swaminath G., Weiszmann J., Cardozo M., Greenberg J., et al. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Molecular Pharmacology 2008, 74:1599-1609.
85. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., Unger R.H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10878-10882.
86. Lefkowitz R.J. Seven transmembrane receptors: Something old, something new. Acta Physiologica 2007, 190:9-19.
87. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
88. Liaw C.W., Connolly D.T. Sequence polymorphisms provide a common consensus sequence for GPR41 and GPR42. DNA and Cell Biology 2009, 28:555-560.
89. Libert F., Parmentier M., Lefort A., Dinsart C., Van Sande J., Maenhaut C., et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 1989, 244:569-572.
90. Liu S., Stampfer M.J., Hu F.B., Giovannucci E., Rimm E., Manson J.E., et al. Whole-grain consumption and risk of coronary heart disease: Results from the nurses' health study. The American Journal of Clinical Nutrition 1999, 70:412-419.
91. Longo W.E., Ballantyne G.H., Savoca P.E., Adrian T.E., Bilchik A.J., Modlin I.M. Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. Scandinavian Journal of Gastroenterology 1991, 26:442-448.
92. Lu S.Y., Jiang Y.J., Lv J., Wu T.X., Yu Q.S., Zhu W.L. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions. Journal of Molecular Graphics & Modelling 2010, 28:766-774.
93. Ludwig D.S., Pereira M.A., Kroenke C.H., Hilner J.E., Van Horn L., Slattery M.L., et al. Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. Journal of American Medical Association 1999, 282:1539-1546.
94. Lundstrom K. An overview on GPCRs and drug discovery: Structure-based drug design and structural biology on GPCRs. Methods in Molecular Biology 2009, 552:51-66.
95. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002, 51:S434-S442.
96. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
97. McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., Bigham E., Briscoe C.P., et al. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorganic & Medicinal Chemistry Letters 2007, 17:1584-1589.
98. Meyer K.A., Kushi L.H., Jacobs D.R., Slavin J., Sellers T.A., Folsom A.R. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. The American Journal of Clinical Nutrition 2000, 71:921-930.
99. Michino M., Abola E., Broks C.L., Dixon J.S., Moult J., Stevens R.C. Community-wide assessment of GPCR structure modeling and ligand docking: GPCR Dock 2008. Nature Reviews. Drug Discovery 2009, 8:455-463.
100. Milligan G. Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends in Pharmacological Sciences 2000, 21:24-28.
101. Milligan G. Strategies to identify ligands for orphan G-protein-coupled receptors. Biochemical Society Transactions 2002, 30:789-793.
102. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: A current perspective. Molecular Pharmacology 2003, 64:1271-1276.
103. Milligan G. Principles: Extending the utility of [35S]GTP gamma S binding assays. Trends in Pharmacological Sciences 2003, 24:87-90.
104. Milligan G., Marshall F., Rees S. G16 as a universal G protein adapter: Implications for agonist screening strategies. Trends in Pharmacological Sciences 1996, 17:235-237.
105. Milligan G., Stoddart L.A., Brown A.J. G protein-coupled receptors for free fatty acids. Cellular Signalling 2006, 18:1360-1365.
106. Milligan G., Stoddart L.A., Smith N.J. Agonism and allosterism: The pharmacology of the free fatty acid receptors FFA2 and FFA3. British Journal of Pharmacology 2009, 158:146-153.
107. Miyauchi S., Hirasawa A., Iga T., Liu N., Itsubo C., Sadakane K., et al. Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn-Schmiedeberg's Archives of Pharmacology 2009, 379:427-434.
108. Mobarec J.C., Sanchez R., Filizola M. Modern homology modeling of G-protein coupled receptors: Which structural template to use?. Journal of Medicinal Chemistry 2009, 52:5207-5216.
109. Morgan N.G., Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochemical Pharmacology 2009, 78:1419-1427.
110. Nagasumi K., Esaki R., Iwachidow K., Yasuhara Y., Ogi K., Tanaka H., et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009, 58:1067-1076.
111. Negoro N., Sasaki S., Mikami I., Suzuki M., Tsujihata Y., Ito R., et al. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Medicinal Chemistry Letters 2010, 1:290-294.
112. Nicolucci A., Rossi M.C. Incretin-based therapies: A new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomedica 2008, 79:184-191.
113. Nilsson N.E., Kotarsky K., Owman C., Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochemical and Biophysical Research Communications 2003, 303:1047-1052.
114. Ogawa T., Hiose H., Miyashita K., Saito I., Saruta T. GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism 2005, 54:296-299.
115. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
116. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289:739-745.
117. Perez D.M. The evolutionarily triumphant G-protein-coupled receptor. Molecular Pharmacology 2003, 63:1202-1205.
118. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nature Reviews. Molecular Cell Biology 2002, 3:639-650.
119. Pouteau E., Nguyen P., Ballevre O., Krempf M. Production rates and metabolism of short-chain fatty acids in the colon and whole body using stable isotopes. The Proceedings of the Nutrition Society 2003, 62:87-93.
120. Prentki M., Joly E., El-Assaad W., Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: Role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002, 51:S405-S413.
121. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. The Journal of Clinical Investigation 2006, 116:1802-1812.
122. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450:383-387.
123. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 2011, 469:175-180.
124. Rayasam G.V., Tulasi V.K., Davis J.A., Bansal V.S. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opinion on Therapeutic Targets 2007, 11:661-671.
125. Rees S. Functional assay systems for drug discovery at G-protein coupled receptors and ion channels. Receptors & Channels 2002, 8:257-259.
126. Sabirsh A., Bywater R.P., Bristulf J., Owman C., Haeggstrom J.Z. Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. Biochemistry 2006, 45:5733-5744.
127. Salehi A., Flodgren E., Nilsson N.E., Jimenez-Feltstrom J., Miyazaki J., Owman C., et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell and Tissue Research 2005, 322:207-215.
128. Sawzdargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F., O'Dowd B.F. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochemical and Biophysical Research Communications 1997, 239:543-547.
129. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Frauss N., Choe H.W., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455:497-502.
130. Schmidt J., Smith N.J., Christiansen E., Tikhonova I.G., Grundmann M., Hudson B.D., et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: Identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. The Journal of Biological Chemistry 2011, 286:10628-10640.
131. Seifert R., Wenzel-Seifert K., Kobilka B.K. GPCR-galpha fusion proteins: Molecular analysis of receptor-G-protein coupling. Trends in Pharmacological Sciences 1999, 20:383-389.
132. Shapiro H., Shachar S., Sekler I., Hershfinkel M., Walker M.D. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochemical and Biophysical Research Communications 2005, 335:97-104.
133. Sina C., Gavrilova O., Forster M., Till A., Derer S., Hildebrand F., et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. The Journal of Immunology 2009, 183:7514-7522.
134. Sleeth M.L., Thompson E.L., Ford H.E., Zac-Varghese S.E., Frost G. Free fatty acid receptor 2 and nutrient sensing: A proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutrition Research Reviews 2010, 23:135-145.
135. Smith N.J., Bennett K.A., Milligan G. When simple agonism is not enough: Emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology 2011, 331:241-247.
136. Smith N.J., Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes. Pharmacological Reviews 2010, 62:701-725.
137. Smith N.J., Stoddart L.A., Devine N.M., Jenkins L., Milligan G. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. The Journal of Biological Chemistry 2009, 284:17527-17539.
138. Song F., Lu S., Gunnet J., Xu J.Z., Wines P., Proost J., et al. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. Journal of Medicinal Chemistry 2007, 50:2807-2817.
139. Soudijn W., Van Wijngaarden I., IJzerman A.P. Allosteric modulation of G protein-coupled receptors: Perspectives and recent developments. Drug Discovery Today 2004, 9:752-758.
140. Steneberg P., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabolism 2005, 1:245-258.
141. Stitham J., Stojanovic A., Merenick B.L., O'Hara K.A., Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. The Journal of Biological Chemistry 2003, 278:4250-4257.
142. Stoddart L.A., Brown A.J., Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: High apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Molecular Pharmacology 2007, 71:994-1005.
143. Stoddart L.A., Milligan G. Constitutive activity of GPR40/FFA1 intrinsic or assay dependent?. Methods in Enzymology 2010, 484:569-590.
144. Stoddart L.A., Smith N.J., Jenkins L., Brown A.J., Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. The Journal of Biological Chemistry 2008, 283:32913-32924.
145. Stoddart L.A., Smith N.J., Milligan G. International union of pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: Pharmacology and pathophysiological functions. Pharmacological Reviews 2008, 60:405-417.
146. Sum C.S., Tikhonova I.G., Neumann S., Engel S., Raaka B.M., Costanzi S., et al. Identification of residues important for agonist recognition and activation in GPR40. The Journal of Biological Chemistry 2007, 282:29248-29255.
147. Summers R.J. Editorial. British Journal of Pharmacology 2010, 159:983-985.
148. Sum C.S., Tikhonova I.G., Costanzi S., Gershengorn M.C. Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. The Journal of Biological Chemistry 2009, 284:3529-3536.
149. Sun Q., Hirasawa A., Hara T., Kimura I., Adachi T., Awaji T., et al. Structure-activity relationships of GPR120 agonists based on a docking simulation. Molecular Pharmacology 2010, 78:804-810.
150. Suzuki N., Suzuki M., Asakawa T., Kataoka O. Remedy for Diabetes 2006, Takeda Pharmaceuticals. WO2006011615.
151. Suzuki T., Igari S., Hirasawa A., Hata M., Ishiguro M., Fujieda H., et al. Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. Journal of Medicinal Chemistry 2008, 51:7640-7644.
152. Szekeres P.G. Functional assays for identifying ligands at orphan G protein-coupled receptors. Receptors & Channels 2002, 8:297-308.
153. Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Letters 2002, 520:97-101.
154. Takeda S., Yamamoto A., Okada T., Matsumura E., Nose E., Kogure K., et al. Identification of surrogate ligands for orphan G protein-coupled receptors. Life Sciences 2003, 74:367-377.
155. Tammino P.J., Copland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008, 47:5481-5492.
156. Tan C.P., Feng Y., Zhou Y.P., Eiermann G.J., Petrov A., Zhou C., et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57:2211-2219.
157. Tanaka T., Yano T., Adachi T., Koshimizu T.A., Hirasawa A., Tsujimoto G. Cloning and characterization of the rat free fatty acid receptor GPR120: In vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn-Schmiedeberg's Archives of Pharmacology 2008, 377:515-522.
158. Tazoe H., Otomo Y., Karaki S., Kato I., Fukami Y., Terasaki M., et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomedical Research 2009, 30:149-156.
159. Thomsen C., Storm H., Holst J.J., Hermansen K. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. The American Journal of Clinical Nutrition 2003, 77:605-611.
160. Tikhonova I.G., Fourmy D. The family of G protein-coupled receptors: An example of membrane proteins. Methods in Molecular Biology 2010, 654:441-454.
161. Tikhonova I.G., Sum C.S., Neumann S., Engel S., Raaka B.M., Costanzi S., et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. Journal of Medicinal Chemistry 2008, 51:625-633.
162. Tikhonova I.G., Sum C.S., Neumann S., Thomas C.J., Raaka B.M., Costanzi S., et al. Bidirectional, iterative approach to the structural delineation of the functional " chemoprint" in GPR40 for agonist recognition. Journal of Medicinal Chemistry 2007, 50:2981-2989.
163. Tomita T., Masuzaki H., Noguchi M., Iwakura H., Fujikura J., Tanaka T., et al. GPR40 gene expression in human pancreas and insulinoma. Biochemical and Biophysical Research Communications 2005, 338:1788-1790.
164. Treem W.R., Ahsan N., Shoup M., Hyams J.S. Fecal short-chain fatty acids in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 1994, 18:159-164.
165. Tunaru S., Lattig J., Kero J., Krause G., Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Molecular Pharmacology 2005, 68:1271-1280.
166. Tyndall J.D., Sandilya R. GPCR agonists and antagonists in the clinic. Medicinal Chemistry 2005, 1:405-421.
167. Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E., Mortrud M.T., et al. The G protein-coupled receptor repertoires of human and mouse. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4903-4908.
168. Venkataraman C., Kuo F. The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. Immunology Letters 2005, 101:144-153.
169. Vettor R., Granzotto M., De Stefani D., Trevellin E., Rossato M., Farina M.G., et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. The Journal of Clinical Endocrinology and Metabolism 2008, 93:3541-3550.
170. Wang A., Gu Z., Heid B., Akers R.M., Jiang H. Identification and characterization of the bovine G protein-coupled receptor GPR41 and GPR43 genes. Journal of Dairy Science 2009, 92:2696-2705.
171. Wang J., Wu X., Simonavicius N., Tian H., Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. The Journal of Biological Chemistry 2006, 281:34457-34464.
172. Wang Y., Jiao X., Kayser F., Liu J., Wang Z., Wanska M., et al. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Bioorganic & Medicinal Chemistry Letters 2010, 20:493-498.
173. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454:486-491.
174. Wilson S., Bergsma D.J., Chambers J.K., Muir A.I., Fantom K.G., Ellis C., et al. Orphan G-protein-coupled receptors: The next generation of drug targets?. British Journal of Pharmacology 1998, 125:1387-1392.
175. Wise A., Jupe S.C., Rees S. The identification of ligands at orphan G-protein coupled receptors. Annual Review of Pharmacology and Toxicology 2004, 44:43-66.
176. Wittenberger T., Schaller H.C., Hellebrand S. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. Journal of Molecular Biology 2001, 307:799-813.
177. Wong J.M., de Souza R., Kendall C.W., Emam A., Jenkins D.J. Colonic health: Fermentation and short chain fatty acids. Journal of Clinical Gastroenterology 2006, 40:235-243.
178. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
179. Wu P., Yang L., Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochemical and Biophysical Research Communications 2010, 403:36-39.
180. Xiong Y., Miyamoto N., Shibata K., Valasek M.A., Motoike T., Kedzierski R.M., et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1045-1050.
181. Yin H., Chu A., Li W., Wang B., Shelton F., Otero F., et al. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. The Journal of Biological Chemistry 2009, 284:12328-12338.
182. Yonezawa T., Haga S., Kobayashi Y., Katoh K., Obara Y. Unsaturated fatty acids promote proliferation via ERK1/2 and akt pathway in bovine mammary epithelial cells. Biochemical and Biophysical Research Communications 2008, 367:729-735.
183. Yonezawa T., Katoh K., Obara Y. Existence of GPR40 functioning in a human breast cancer cell line, MCF-7. Biochemical and Biophysical Research Communications 2004, 314:805-809.
184. Yousefi S., Cooper P.R., Potter S.L., Mueck B., Jarai G. Cloning and expression analysis of a novel G-protein-coupled receptor selectively expressed on granulocytes. Journal of Leukocyte Biology 2001, 69:1045-1052.
185. Zaibi M.S., Stocker C.J., O'Dowd J., Davies A., Bellahcene M., Cawthorne M.A., et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Letters 2010, 584:2381-2386.
186. Zhang X., Yan G., Li Y., Zhu W., Wang H. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese zucker rats. Biomedicine & Pharmacotherapy 2010, 64:647-651.
187. Zhou J., Martin R.J., Tulley R.T., Raggio A.M., McCutcheon K.L., Shen L., et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. American Journal of Physiology. Endocrinology and Metabolism 2008, 295:E1160-E1166.